{"id":90992,"date":"2016-12-07T12:16:33","date_gmt":"2016-12-07T12:16:33","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=90992"},"modified":"2016-12-07T12:16:33","modified_gmt":"2016-12-07T12:16:33","slug":"new-study-mycobacterium-tuberculosis-protein-ag85a-pipeline-market-review-h2-2016-by-radiant-insights","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/new-study-mycobacterium-tuberculosis-protein-ag85a-pipeline-market-review-h2-2016-by-radiant-insights_90992.html","title":{"rendered":"New Study: Mycobacterium tuberculosis Protein Ag85A Pipeline Market Review, H2 2016 by Radiant Insights"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Radiant Insights”<\/div>\n<\/div>\n<\/div>\n
RadiantInsights.com includes new market research report on “Mycobacterium tuberculosis Protein Ag85A – Pipeline Review, H2 2016” to its huge collection of research reports.<\/div>\n

Summary<\/strong>
Global Markets Direct’s, ‘Mycobacterium tuberculosis Protein Ag85A – Pipeline Review, H2 2016’, provides in depth analysis on Mycobacterium tuberculosis Protein Ag85A targeted pipeline therapeutics.<\/p>\n

The report provides comprehensive information on the Mycobacterium tuberculosis Protein Ag85A, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics development and features dormant and discontinued projects.<\/p>\n

Access Full Report with TOC @ http:\/\/www.radiantinsights.com\/research\/mycobacterium-tuberculosis-protein-ag85a-pipeline-review-h2-2016<\/a><\/strong><\/p>\n

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.<\/p>\n

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<\/p>\n

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.<\/p>\n

Related reports by Radiant Insights:<\/strong>
P27 (Negative Regulatory Factor or Nef) – Pipeline Review, H2 2016 – <\/strong>
http:\/\/www.radiantinsights.com\/research\/p27-negative-regulatory-factor-or-nef-pipeline-review-h2-2016<\/strong><\/a><\/p>\n

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) – Pipeline Review, H2 2016 – <\/strong>
http:\/\/www.radiantinsights.com\/research\/interleukin-17-receptor-a-cdw217-or-cd217-or-il17ra-pipeline-review-h2-2016<\/strong><\/a><\/p>\n

Scope<\/strong>
– The report provides a snapshot of the global therapeutic landscape for Mycobacterium tuberculosis Protein Ag85A
– The report reviews Mycobacterium tuberculosis Protein Ag85A targeted therapeutics under development by companies and universities\/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics and enlists all their major and minor projects
– The report assesses Mycobacterium tuberculosis Protein Ag85A targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Mycobacterium tuberculosis Protein Ag85A targeted therapeutics<\/p>\n

Reasons to buy<\/strong>
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Mycobacterium tuberculosis Protein Ag85A
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Mycobacterium tuberculosis Protein Ag85A development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope<\/p>\n

Browse More Categories @ http:\/\/www.radiantinsights.com\/catalogs<\/a><\/strong><\/p>\n

Table of Contents<\/strong>
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mycobacterium tuberculosis Protein Ag85A Overview 6
Therapeutics Development 7
Mycobacterium tuberculosis Protein Ag85A – Products under Development by Stage of Development 7
Mycobacterium tuberculosis Protein Ag85A – Products under Development by Therapy Area 8
Mycobacterium tuberculosis Protein Ag85A – Products under Development by Indication 9
Mycobacterium tuberculosis Protein Ag85A – Pipeline Products Glance 10
Early Stage Products 10
Mycobacterium tuberculosis Protein Ag85A – Products under Development by Companies 11
Mycobacterium tuberculosis Protein Ag85A – Products under Development by Universities\/Institutes 13
Mycobacterium tuberculosis Protein Ag85A – Therapeutics Assessment 15
Assessment by Monotherapy\/Combination Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Mycobacterium tuberculosis Protein Ag85A – Companies Involved in Therapeutics Development 20
Imaxio SA 20<\/p>\n

Buy a Sample copy of This Report @ http:\/\/www.radiantinsights.com\/research\/mycobacterium-tuberculosis-protein-ag85a-pipeline-review-h2-2016\/request-sample<\/a><\/strong><\/p>\n

About Us:<\/strong>
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships\/ tie-ups and customized research solutions.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Radiant Insights, Inc.
Contact Person:<\/strong> Michelle Thoras, Corporate Sales Specialist – USA
Email:<\/strong> sales@radiantinsights.com
Phone:<\/strong> (415) 349-0054, Toll Free: 1-888-202-9519
Address:<\/strong>28 2nd Street, Suite 3036
City:<\/strong> San Francisco
State:<\/strong> California
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.radiantinsights.com\/research\/mycobacterium-tuberculosis-protein-ag85a-pipeline-review-h2-2016<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Radiant Insights” RadiantInsights.com includes new market research report on “Mycobacterium tuberculosis Protein Ag85A – Pipeline Review, H2 2016” to its huge collection of research reports. SummaryGlobal Markets Direct’s, ‘Mycobacterium tuberculosis Protein Ag85A – Pipeline Review, H2 2016’, provides in depth … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-90992","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/90992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=90992"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/90992\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=90992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=90992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=90992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}